OPNT News and Press, Opiant Pharmaceuticals Inc. From 11/12/19

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q3 GAAP EPS of $1.97 beats by $2.10 . Revenue of $20.64M (+372.3% Y/Y) beats by $15.12M . Press Release More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

SANTA MONICA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the third quarter and nine m...

SANTA MONICA, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the third quarter and ...

Noteworthy events during the week of October 13 - 19 for healthcare investors. More news on: Flexion Therapeutics, Inc., Johnson & Johnson, ArQule, Inc., Healthcare stocks news, , Read more ...

SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that Chief Executive Officer, Roger Crystal, M.D., and...

SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that it will present at the 2019 Cantor Global Healthcare ...

Editor's note: Seeking Alpha is proud to welcome Replix Research Group LLC as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Writ...

SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, will present at the following upcoming investor conferences: 2019 Wells...

Opiant Pharmaceuticals, Inc (OPNT) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Lisa Sher – Senior Director of Investor Relations and Communications Roger Crystal – Chief Executive Officer David O'Toole – Chief Financial Off...

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q2 EPS of $0.31 may not be comparable to consensus of -$0.55. More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...